Drug Trial Radar · NCT00506922
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Last checked: Nov 19, 2026Latest source record: Apr 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Sep 2000
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Astex Pharmaceuticals, Inc.
- First posted
- Jul 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: 1\. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one antigen mismatched related donor transplantation. Secondary Objectives: 1. To determine safety of escalating doses of pentostatin in combination with tacrolimus and methotrexate. 2. To reduce the incidence of acute GVHD following transplants with unrelated donor to 40%. 3. To document blood levels of tacrolimus when combined with pentostatin.
Conditions
- Leukemia
- Lymphoma
Interventions
PentostatinDrug
Given intravenously on days +8, +15, +22 and +30 post transplant: Group 2 - Pentostatin 0.5 mg/m\^2 Group 3 - Pentostatin 1 mg/m\^2 Group 4 - Pentostatin 1.5 mg/m\^2 Group 5 - Pentostatin 2 mg/m\^2
TacrolimusDrug
Given intravenously from day -2, and will be switched to oral dosing when tolerated.
MethotrexateDrug
Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Without GVHD at 100 DaysTime frame: 100 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
U.T.M.D. Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.